Medical Care
Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Research Report 2025
- Mar 11, 25
- ID: 9350
- Pages: 82
- Figures: 81
- Views: 20
The global market for Paroxysmal Nocturnal Hemoglobinuria Treatment was valued at US$ 3642 million in the year 2024 and is projected to reach a revised size of US$ 6393 million by 2031, growing at a CAGR of 8.5% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Paroxysmal Nocturnal Hemoglobinuria Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Paroxysmal Nocturnal Hemoglobinuria Treatment.
The Paroxysmal Nocturnal Hemoglobinuria Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Paroxysmal Nocturnal Hemoglobinuria Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Paroxysmal Nocturnal Hemoglobinuria Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Achillion Pharmaceuticals Inc
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Amgen Inc
Apellis Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
ISU ABXIS Co Ltd
Novartis AG
NovelMed Therapeutics Inc
Omeros Corp
Ra Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Regenesance BV
Segment by Type
ACH-4471
ALN-CC5
ALXN-1210
AMY-101
APL-2
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Paroxysmal Nocturnal Hemoglobinuria Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Paroxysmal Nocturnal Hemoglobinuria Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Paroxysmal Nocturnal Hemoglobinuria Treatment.
The Paroxysmal Nocturnal Hemoglobinuria Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Paroxysmal Nocturnal Hemoglobinuria Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Paroxysmal Nocturnal Hemoglobinuria Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Achillion Pharmaceuticals Inc
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Amgen Inc
Apellis Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
ISU ABXIS Co Ltd
Novartis AG
NovelMed Therapeutics Inc
Omeros Corp
Ra Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Regenesance BV
Segment by Type
ACH-4471
ALN-CC5
ALXN-1210
AMY-101
APL-2
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Paroxysmal Nocturnal Hemoglobinuria Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 ACH-4471
1.2.3 ALN-CC5
1.2.4 ALXN-1210
1.2.5 AMY-101
1.2.6 APL-2
1.2.7 Others
1.3 Market by Application
1.3.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Perspective (2020-2031)
2.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Growth Trends by Region
2.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Size by Region (2020-2025)
2.2.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Region (2026-2031)
2.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Dynamics
2.3.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Industry Trends
2.3.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Drivers
2.3.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Challenges
2.3.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Revenue
3.1.1 Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Revenue (2020-2025)
3.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue
3.4 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Concentration Ratio
3.4.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue in 2024
3.5 Global Key Players of Paroxysmal Nocturnal Hemoglobinuria Treatment Head office and Area Served
3.6 Global Key Players of Paroxysmal Nocturnal Hemoglobinuria Treatment, Product and Application
3.7 Global Key Players of Paroxysmal Nocturnal Hemoglobinuria Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Type
4.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Size by Type (2020-2025)
4.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Type (2026-2031)
5 Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Application
5.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Size by Application (2020-2025)
5.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2020-2031)
6.2 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025)
6.4 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2020-2031)
7.2 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025)
7.4 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2020-2031)
8.2 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2020-2031)
9.2 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025)
9.4 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2020-2031)
10.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Achillion Pharmaceuticals Inc
11.1.1 Achillion Pharmaceuticals Inc Company Details
11.1.2 Achillion Pharmaceuticals Inc Business Overview
11.1.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.1.4 Achillion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.1.5 Achillion Pharmaceuticals Inc Recent Development
11.2 Akari Therapeutics Plc
11.2.1 Akari Therapeutics Plc Company Details
11.2.2 Akari Therapeutics Plc Business Overview
11.2.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.2.4 Akari Therapeutics Plc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.2.5 Akari Therapeutics Plc Recent Development
11.3 Alexion Pharmaceuticals Inc
11.3.1 Alexion Pharmaceuticals Inc Company Details
11.3.2 Alexion Pharmaceuticals Inc Business Overview
11.3.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.3.4 Alexion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.3.5 Alexion Pharmaceuticals Inc Recent Development
11.4 Alnylam Pharmaceuticals Inc
11.4.1 Alnylam Pharmaceuticals Inc Company Details
11.4.2 Alnylam Pharmaceuticals Inc Business Overview
11.4.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.4.4 Alnylam Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.4.5 Alnylam Pharmaceuticals Inc Recent Development
11.5 Amgen Inc
11.5.1 Amgen Inc Company Details
11.5.2 Amgen Inc Business Overview
11.5.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.5.4 Amgen Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.5.5 Amgen Inc Recent Development
11.6 Apellis Pharmaceuticals Inc
11.6.1 Apellis Pharmaceuticals Inc Company Details
11.6.2 Apellis Pharmaceuticals Inc Business Overview
11.6.3 Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.6.4 Apellis Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.6.5 Apellis Pharmaceuticals Inc Recent Development
11.7 F. Hoffmann-La Roche Ltd
11.7.1 F. Hoffmann-La Roche Ltd Company Details
11.7.2 F. Hoffmann-La Roche Ltd Business Overview
11.7.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.7.4 F. Hoffmann-La Roche Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.7.5 F. Hoffmann-La Roche Ltd Recent Development
11.8 ISU ABXIS Co Ltd
11.8.1 ISU ABXIS Co Ltd Company Details
11.8.2 ISU ABXIS Co Ltd Business Overview
11.8.3 ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.8.4 ISU ABXIS Co Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.8.5 ISU ABXIS Co Ltd Recent Development
11.9 Novartis AG
11.9.1 Novartis AG Company Details
11.9.2 Novartis AG Business Overview
11.9.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.9.4 Novartis AG Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.9.5 Novartis AG Recent Development
11.10 NovelMed Therapeutics Inc
11.10.1 NovelMed Therapeutics Inc Company Details
11.10.2 NovelMed Therapeutics Inc Business Overview
11.10.3 NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.10.4 NovelMed Therapeutics Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.10.5 NovelMed Therapeutics Inc Recent Development
11.11 Omeros Corp
11.11.1 Omeros Corp Company Details
11.11.2 Omeros Corp Business Overview
11.11.3 Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.11.4 Omeros Corp Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.11.5 Omeros Corp Recent Development
11.12 Ra Pharmaceuticals Inc
11.12.1 Ra Pharmaceuticals Inc Company Details
11.12.2 Ra Pharmaceuticals Inc Business Overview
11.12.3 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.12.4 Ra Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.12.5 Ra Pharmaceuticals Inc Recent Development
11.13 Regeneron Pharmaceuticals Inc
11.13.1 Regeneron Pharmaceuticals Inc Company Details
11.13.2 Regeneron Pharmaceuticals Inc Business Overview
11.13.3 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.13.4 Regeneron Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.13.5 Regeneron Pharmaceuticals Inc Recent Development
11.14 Regenesance BV
11.14.1 Regenesance BV Company Details
11.14.2 Regenesance BV Business Overview
11.14.3 Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.14.4 Regenesance BV Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.14.5 Regenesance BV Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 ACH-4471
1.2.3 ALN-CC5
1.2.4 ALXN-1210
1.2.5 AMY-101
1.2.6 APL-2
1.2.7 Others
1.3 Market by Application
1.3.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Perspective (2020-2031)
2.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Growth Trends by Region
2.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Size by Region (2020-2025)
2.2.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Region (2026-2031)
2.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Dynamics
2.3.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Industry Trends
2.3.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Drivers
2.3.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Challenges
2.3.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Revenue
3.1.1 Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Revenue (2020-2025)
3.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue
3.4 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Concentration Ratio
3.4.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue in 2024
3.5 Global Key Players of Paroxysmal Nocturnal Hemoglobinuria Treatment Head office and Area Served
3.6 Global Key Players of Paroxysmal Nocturnal Hemoglobinuria Treatment, Product and Application
3.7 Global Key Players of Paroxysmal Nocturnal Hemoglobinuria Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Type
4.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Size by Type (2020-2025)
4.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Type (2026-2031)
5 Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Application
5.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Size by Application (2020-2025)
5.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2020-2031)
6.2 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025)
6.4 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2020-2031)
7.2 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025)
7.4 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2020-2031)
8.2 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2020-2031)
9.2 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025)
9.4 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2020-2031)
10.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Achillion Pharmaceuticals Inc
11.1.1 Achillion Pharmaceuticals Inc Company Details
11.1.2 Achillion Pharmaceuticals Inc Business Overview
11.1.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.1.4 Achillion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.1.5 Achillion Pharmaceuticals Inc Recent Development
11.2 Akari Therapeutics Plc
11.2.1 Akari Therapeutics Plc Company Details
11.2.2 Akari Therapeutics Plc Business Overview
11.2.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.2.4 Akari Therapeutics Plc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.2.5 Akari Therapeutics Plc Recent Development
11.3 Alexion Pharmaceuticals Inc
11.3.1 Alexion Pharmaceuticals Inc Company Details
11.3.2 Alexion Pharmaceuticals Inc Business Overview
11.3.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.3.4 Alexion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.3.5 Alexion Pharmaceuticals Inc Recent Development
11.4 Alnylam Pharmaceuticals Inc
11.4.1 Alnylam Pharmaceuticals Inc Company Details
11.4.2 Alnylam Pharmaceuticals Inc Business Overview
11.4.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.4.4 Alnylam Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.4.5 Alnylam Pharmaceuticals Inc Recent Development
11.5 Amgen Inc
11.5.1 Amgen Inc Company Details
11.5.2 Amgen Inc Business Overview
11.5.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.5.4 Amgen Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.5.5 Amgen Inc Recent Development
11.6 Apellis Pharmaceuticals Inc
11.6.1 Apellis Pharmaceuticals Inc Company Details
11.6.2 Apellis Pharmaceuticals Inc Business Overview
11.6.3 Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.6.4 Apellis Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.6.5 Apellis Pharmaceuticals Inc Recent Development
11.7 F. Hoffmann-La Roche Ltd
11.7.1 F. Hoffmann-La Roche Ltd Company Details
11.7.2 F. Hoffmann-La Roche Ltd Business Overview
11.7.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.7.4 F. Hoffmann-La Roche Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.7.5 F. Hoffmann-La Roche Ltd Recent Development
11.8 ISU ABXIS Co Ltd
11.8.1 ISU ABXIS Co Ltd Company Details
11.8.2 ISU ABXIS Co Ltd Business Overview
11.8.3 ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.8.4 ISU ABXIS Co Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.8.5 ISU ABXIS Co Ltd Recent Development
11.9 Novartis AG
11.9.1 Novartis AG Company Details
11.9.2 Novartis AG Business Overview
11.9.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.9.4 Novartis AG Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.9.5 Novartis AG Recent Development
11.10 NovelMed Therapeutics Inc
11.10.1 NovelMed Therapeutics Inc Company Details
11.10.2 NovelMed Therapeutics Inc Business Overview
11.10.3 NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.10.4 NovelMed Therapeutics Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.10.5 NovelMed Therapeutics Inc Recent Development
11.11 Omeros Corp
11.11.1 Omeros Corp Company Details
11.11.2 Omeros Corp Business Overview
11.11.3 Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.11.4 Omeros Corp Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.11.5 Omeros Corp Recent Development
11.12 Ra Pharmaceuticals Inc
11.12.1 Ra Pharmaceuticals Inc Company Details
11.12.2 Ra Pharmaceuticals Inc Business Overview
11.12.3 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.12.4 Ra Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.12.5 Ra Pharmaceuticals Inc Recent Development
11.13 Regeneron Pharmaceuticals Inc
11.13.1 Regeneron Pharmaceuticals Inc Company Details
11.13.2 Regeneron Pharmaceuticals Inc Business Overview
11.13.3 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.13.4 Regeneron Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.13.5 Regeneron Pharmaceuticals Inc Recent Development
11.14 Regenesance BV
11.14.1 Regenesance BV Company Details
11.14.2 Regenesance BV Business Overview
11.14.3 Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.14.4 Regenesance BV Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
11.14.5 Regenesance BV Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of ACH-4471
Table 3. Key Players of ALN-CC5
Table 4. Key Players of ALXN-1210
Table 5. Key Players of AMY-101
Table 6. Key Players of APL-2
Table 7. Key Players of Others
Table 8. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 11. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Region (2020-2025)
Table 12. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 13. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Region (2026-2031)
Table 14. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Trends
Table 15. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Drivers
Table 16. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Challenges
Table 17. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Restraints
Table 18. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Players (2020-2025)
Table 20. Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment as of 2024)
Table 21. Ranking of Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Paroxysmal Nocturnal Hemoglobinuria Treatment, Headquarters and Area Served
Table 24. Global Key Players of Paroxysmal Nocturnal Hemoglobinuria Treatment, Product and Application
Table 25. Global Key Players of Paroxysmal Nocturnal Hemoglobinuria Treatment, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2020-2025) & (US$ Million)
Table 28. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Type (2020-2025)
Table 29. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 30. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Type (2026-2031)
Table 31. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2020-2025) & (US$ Million)
Table 32. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Application (2020-2025)
Table 33. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 34. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Application (2026-2031)
Table 35. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 37. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 38. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 39. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 40. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 41. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 42. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 43. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2026-2031) & (US$ Million)
Table 44. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 46. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 47. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 48. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 49. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 50. Achillion Pharmaceuticals Inc Company Details
Table 51. Achillion Pharmaceuticals Inc Business Overview
Table 52. Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 53. Achillion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 54. Achillion Pharmaceuticals Inc Recent Development
Table 55. Akari Therapeutics Plc Company Details
Table 56. Akari Therapeutics Plc Business Overview
Table 57. Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 58. Akari Therapeutics Plc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 59. Akari Therapeutics Plc Recent Development
Table 60. Alexion Pharmaceuticals Inc Company Details
Table 61. Alexion Pharmaceuticals Inc Business Overview
Table 62. Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 63. Alexion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 64. Alexion Pharmaceuticals Inc Recent Development
Table 65. Alnylam Pharmaceuticals Inc Company Details
Table 66. Alnylam Pharmaceuticals Inc Business Overview
Table 67. Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 68. Alnylam Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 69. Alnylam Pharmaceuticals Inc Recent Development
Table 70. Amgen Inc Company Details
Table 71. Amgen Inc Business Overview
Table 72. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 73. Amgen Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 74. Amgen Inc Recent Development
Table 75. Apellis Pharmaceuticals Inc Company Details
Table 76. Apellis Pharmaceuticals Inc Business Overview
Table 77. Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 78. Apellis Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 79. Apellis Pharmaceuticals Inc Recent Development
Table 80. F. Hoffmann-La Roche Ltd Company Details
Table 81. F. Hoffmann-La Roche Ltd Business Overview
Table 82. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 83. F. Hoffmann-La Roche Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 84. F. Hoffmann-La Roche Ltd Recent Development
Table 85. ISU ABXIS Co Ltd Company Details
Table 86. ISU ABXIS Co Ltd Business Overview
Table 87. ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 88. ISU ABXIS Co Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 89. ISU ABXIS Co Ltd Recent Development
Table 90. Novartis AG Company Details
Table 91. Novartis AG Business Overview
Table 92. Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 93. Novartis AG Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 94. Novartis AG Recent Development
Table 95. NovelMed Therapeutics Inc Company Details
Table 96. NovelMed Therapeutics Inc Business Overview
Table 97. NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 98. NovelMed Therapeutics Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 99. NovelMed Therapeutics Inc Recent Development
Table 100. Omeros Corp Company Details
Table 101. Omeros Corp Business Overview
Table 102. Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 103. Omeros Corp Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 104. Omeros Corp Recent Development
Table 105. Ra Pharmaceuticals Inc Company Details
Table 106. Ra Pharmaceuticals Inc Business Overview
Table 107. Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 108. Ra Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 109. Ra Pharmaceuticals Inc Recent Development
Table 110. Regeneron Pharmaceuticals Inc Company Details
Table 111. Regeneron Pharmaceuticals Inc Business Overview
Table 112. Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 113. Regeneron Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 114. Regeneron Pharmaceuticals Inc Recent Development
Table 115. Regenesance BV Company Details
Table 116. Regenesance BV Business Overview
Table 117. Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 118. Regenesance BV Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 119. Regenesance BV Recent Development
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
Table 123. Authors List of This Report
List of Figures
Figure 1. Paroxysmal Nocturnal Hemoglobinuria Treatment Picture
Figure 2. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type: 2024 VS 2031
Figure 4. ACH-4471 Features
Figure 5. ALN-CC5 Features
Figure 6. ALXN-1210 Features
Figure 7. AMY-101 Features
Figure 8. APL-2 Features
Figure 9. Others Features
Figure 10. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2020-2031) & (US$ Million)
Figure 11. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application: 2024 VS 2031
Figure 12. Hospital Case Studies
Figure 13. Clinic Case Studies
Figure 14. Others Case Studies
Figure 15. Paroxysmal Nocturnal Hemoglobinuria Treatment Report Years Considered
Figure 16. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 17. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Region: 2024 VS 2031
Figure 19. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Players in 2024
Figure 20. Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment as of 2024)
Figure 21. The Top 10 and 5 Players Market Share by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue in 2024
Figure 22. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Country (2020-2031)
Figure 24. United States Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Canada Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Country (2020-2031)
Figure 28. Germany Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. France Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. U.K. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Italy Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Russia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Nordic Countries Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Region (2020-2031)
Figure 36. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. India Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Australia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Country (2020-2031)
Figure 44. Mexico Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Brazil Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Country (2020-2031)
Figure 48. Turkey Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. UAE Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Achillion Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 52. Akari Therapeutics Plc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 53. Alexion Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 54. Alnylam Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 55. Amgen Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 56. Apellis Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 57. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 58. ISU ABXIS Co Ltd Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 59. Novartis AG Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 60. NovelMed Therapeutics Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 61. Omeros Corp Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 62. Ra Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 63. Regeneron Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 64. Regenesance BV Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Table 1. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of ACH-4471
Table 3. Key Players of ALN-CC5
Table 4. Key Players of ALXN-1210
Table 5. Key Players of AMY-101
Table 6. Key Players of APL-2
Table 7. Key Players of Others
Table 8. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 11. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Region (2020-2025)
Table 12. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 13. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Region (2026-2031)
Table 14. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Trends
Table 15. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Drivers
Table 16. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Challenges
Table 17. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Restraints
Table 18. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Players (2020-2025)
Table 20. Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment as of 2024)
Table 21. Ranking of Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Paroxysmal Nocturnal Hemoglobinuria Treatment, Headquarters and Area Served
Table 24. Global Key Players of Paroxysmal Nocturnal Hemoglobinuria Treatment, Product and Application
Table 25. Global Key Players of Paroxysmal Nocturnal Hemoglobinuria Treatment, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2020-2025) & (US$ Million)
Table 28. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Type (2020-2025)
Table 29. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 30. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Type (2026-2031)
Table 31. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2020-2025) & (US$ Million)
Table 32. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Application (2020-2025)
Table 33. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 34. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Application (2026-2031)
Table 35. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 37. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 38. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 39. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 40. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 41. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 42. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 43. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2026-2031) & (US$ Million)
Table 44. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 46. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 47. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 48. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 49. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 50. Achillion Pharmaceuticals Inc Company Details
Table 51. Achillion Pharmaceuticals Inc Business Overview
Table 52. Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 53. Achillion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 54. Achillion Pharmaceuticals Inc Recent Development
Table 55. Akari Therapeutics Plc Company Details
Table 56. Akari Therapeutics Plc Business Overview
Table 57. Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 58. Akari Therapeutics Plc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 59. Akari Therapeutics Plc Recent Development
Table 60. Alexion Pharmaceuticals Inc Company Details
Table 61. Alexion Pharmaceuticals Inc Business Overview
Table 62. Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 63. Alexion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 64. Alexion Pharmaceuticals Inc Recent Development
Table 65. Alnylam Pharmaceuticals Inc Company Details
Table 66. Alnylam Pharmaceuticals Inc Business Overview
Table 67. Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 68. Alnylam Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 69. Alnylam Pharmaceuticals Inc Recent Development
Table 70. Amgen Inc Company Details
Table 71. Amgen Inc Business Overview
Table 72. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 73. Amgen Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 74. Amgen Inc Recent Development
Table 75. Apellis Pharmaceuticals Inc Company Details
Table 76. Apellis Pharmaceuticals Inc Business Overview
Table 77. Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 78. Apellis Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 79. Apellis Pharmaceuticals Inc Recent Development
Table 80. F. Hoffmann-La Roche Ltd Company Details
Table 81. F. Hoffmann-La Roche Ltd Business Overview
Table 82. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 83. F. Hoffmann-La Roche Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 84. F. Hoffmann-La Roche Ltd Recent Development
Table 85. ISU ABXIS Co Ltd Company Details
Table 86. ISU ABXIS Co Ltd Business Overview
Table 87. ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 88. ISU ABXIS Co Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 89. ISU ABXIS Co Ltd Recent Development
Table 90. Novartis AG Company Details
Table 91. Novartis AG Business Overview
Table 92. Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 93. Novartis AG Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 94. Novartis AG Recent Development
Table 95. NovelMed Therapeutics Inc Company Details
Table 96. NovelMed Therapeutics Inc Business Overview
Table 97. NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 98. NovelMed Therapeutics Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 99. NovelMed Therapeutics Inc Recent Development
Table 100. Omeros Corp Company Details
Table 101. Omeros Corp Business Overview
Table 102. Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 103. Omeros Corp Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 104. Omeros Corp Recent Development
Table 105. Ra Pharmaceuticals Inc Company Details
Table 106. Ra Pharmaceuticals Inc Business Overview
Table 107. Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 108. Ra Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 109. Ra Pharmaceuticals Inc Recent Development
Table 110. Regeneron Pharmaceuticals Inc Company Details
Table 111. Regeneron Pharmaceuticals Inc Business Overview
Table 112. Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 113. Regeneron Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 114. Regeneron Pharmaceuticals Inc Recent Development
Table 115. Regenesance BV Company Details
Table 116. Regenesance BV Business Overview
Table 117. Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 118. Regenesance BV Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)
Table 119. Regenesance BV Recent Development
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
Table 123. Authors List of This Report
List of Figures
Figure 1. Paroxysmal Nocturnal Hemoglobinuria Treatment Picture
Figure 2. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type: 2024 VS 2031
Figure 4. ACH-4471 Features
Figure 5. ALN-CC5 Features
Figure 6. ALXN-1210 Features
Figure 7. AMY-101 Features
Figure 8. APL-2 Features
Figure 9. Others Features
Figure 10. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2020-2031) & (US$ Million)
Figure 11. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application: 2024 VS 2031
Figure 12. Hospital Case Studies
Figure 13. Clinic Case Studies
Figure 14. Others Case Studies
Figure 15. Paroxysmal Nocturnal Hemoglobinuria Treatment Report Years Considered
Figure 16. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 17. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Region: 2024 VS 2031
Figure 19. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Players in 2024
Figure 20. Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment as of 2024)
Figure 21. The Top 10 and 5 Players Market Share by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue in 2024
Figure 22. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Country (2020-2031)
Figure 24. United States Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Canada Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Country (2020-2031)
Figure 28. Germany Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. France Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. U.K. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Italy Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Russia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Nordic Countries Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Region (2020-2031)
Figure 36. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. India Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Australia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Country (2020-2031)
Figure 44. Mexico Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Brazil Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Country (2020-2031)
Figure 48. Turkey Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. UAE Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Achillion Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 52. Akari Therapeutics Plc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 53. Alexion Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 54. Alnylam Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 55. Amgen Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 56. Apellis Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 57. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 58. ISU ABXIS Co Ltd Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 59. Novartis AG Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 60. NovelMed Therapeutics Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 61. Omeros Corp Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 62. Ra Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 63. Regeneron Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 64. Regenesance BV Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Allergen Detection Market Research Report 2025
Jun 28, 25
Global Electronic Health Tracking System Market Research Report 2025
Jun 28, 25
Global Speciality Optical Fibers Market Research Report 2025
Jun 28, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232